Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic disease

- Day, Fiona, Sridharan, Swetha, Oldmeadow, Christopher, Martin, Jarad, Johnson, Catherine, Quah, Gaik T., Mallesara, Girish, Kumar, Mahesh, Poulter, Amber-Louise, Morrison, Anthony, van der Westhuizen, Andre, Fraser, Allison

Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

- Weber, Jeffrey S., Schadendorf, Dirk, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Del Vecchio, Michele, Brown, Michael P., Rutkowski, P, Haydon, A, Grob, J-J, Schachter, J, Queirolo, P, de la Cruz-Merino, L, van der Westhuizen, Andre, Menzies, AM, Re, S, Larkin, James, Bas, T, de Pril, V, Braverman, J, Tenney, DJ, Tang, H, Long, GV, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas

Modelled economic evaluation of nivolumab for the treatment of second-line advanced or metastatic squamous non-small-cell lung cancer in Australia using both partition survival and markov models

- Gao, Lan, Li, Shu-Chuen

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis

- Lomax, Anna J., McGuire, Helen M., Gupta, Sandeep K., Hollingsworth, Jane, Kim, Haewon, Fazekas de St Groth, Barbara, McGill, Neil, McNeil, Catriona, Choi, Clara J., Hersey, Peter, Karikios, Deme, Shannon, Kerwin, van Hal, Sebastian, Carr, Urszula, Crotty, Anne